长春瑞滨联合卡培他滨对乳腺癌患者复发转移和无病生存的影响

Influence of vinorelbine combined with capecitabine on recurrence,metas-tasis and disease free survival for patients with mammary cancer

目的探讨长春瑞滨联合卡培他滨对乳腺癌患者复发转移和无病生存的影响。方法选取本院2006年1月-2010年1月收治的乳腺癌患者50例,患者均给予长春瑞滨及卡培他滨化疗,其中行单纯辅助化疗44例,辅助化疗＋内分泌治疗6例。分析患者的近期疗效、中位生存期、不良反应等情况。结果 50例患者中,有效率为40.0%,疾病控制率为82.0%;50例患者中二线治疗应用本方案化疗30例,RR为50.0%,三线治疗及之后应用本方案化疗20例,RR为25.0%;随访3-60个月,50例患者中37例死亡,其中7例为PR患者,21例为SD患者,9例为PD患者;3例CR患者获得4年以上无病生存,3例患者2年后复发或出现新病灶,所有患者的中位无进展生存期为10个月（0-60个月）,中位生存期为16个月（3-60个月）;主要不良反应为骨髓抑制,白细胞减少比例为88.0%,同时伴有恶心呕吐、食欲不振等消化道症状。结论长春瑞滨联合卡培他滨治疗乳腺癌的效果确切,不良反应较少,患者耐受性好,可减少复发转移,延长患者的无病生存期。

Objective To explore the influence of vinorelbine combined with capecitabine on recurrence,metastasis and disease free survival for patients with mammary cancer. Methods 50 patients with mammary cancer treated in our hospital from January 2006 to January 2010 were selected.All patients were given chemotherapy of vinorelbine and capecitabine,among them,44 cases were given simple adjuvant chemotherapy,6 cases were given adjuvant chemothera-py＋endocrine therapy.The short-term curative effect,median survival time and adverse reaction of the patients were analyzed. Results Among 50 patients,the effective rate was 40.0% and disease control rate was 82.0%.This scheme was used for second-line therapy in 30 cases,and RR was 50.0%,while the scheme was used for the third-line treatment or above,and RR was 25.0%;patients were followed-up for 3 to 60 months,37 cases in 50 patients died,among them,7 cases were PR,21 cases were SD,and 9 cases were PD;3 CR patients had disease free survival for over 4 years,3 patients relapsed or new focus appeared 2 years later.Median progression-free survival cycle of all patients was 10 months（0-60 months） and median survival cycle was 16 months（3-60 months）;main adverse effect included myelosuppression,the proportion of leukopenia was 88.0%,and some concomitant gastrointestinal symptoms,such as nausea,vomiting and loss of appetite and so on. Conclusion The effect of vinorelbine combined with capecitabine in the treatment of mammary cancer has exact curative effect with less adverse reaction,and higher tolerance of patients and it can reduce relapse and metastasis and prolong patients′ disease free survival time.